Ryan McBride

Articles by Ryan McBride

Is it too soon to quit on Nabi's nicotine vaccine?

A new study showed a glimmer of hope for a troubled nicotine vaccine after a series of clinical trial setbacks, as investigators hold out hope for new weapons against smoking, a leading cause of deadly cancers, lethal lung disease and other fatal ailments. Yet evidence from the latest study could be too scant to win over some skeptics.

Researchers target multiple tumors in new cancer vaccine study

Targeting a variety of tumor types, the Roswell Park Cancer Institute has begun recruiting patients for an early-stage clinical trial to test an experimental cancer vaccine. The vaccine, or...

Novartis' meningitis B vaccine aces study en route to market

The remaining type of meningitis for which no vaccine exists has finally met its match. In a study backed by Novartis ($NVS), researchers found the Swiss drug giant's experimental vaccine, dubbed...

Twitter as biopharma radar

I initially hated Twitter when I begrudgingly signed up for an account more than three years ago. At that time, I likened it to making news reporters get paper routes to deliver their stories to